Prime Medicine (PRME) shares jumped 8% Friday after the FDA cleared its IND application for PM647, an experimental gene-editing therapy for Alpha-1 Antitrypsin Deficiency.
The clearance allows Prime Medicine (PRME) to begin a Phase 1/2 trial evaluating PM647 in
